**Personal Details**



Name : Caner Süsal

Sex : Male

Profession : Physician

Date of Birth : March 27, 1961

Place of Birth : Konya, Turkey

**Education**

1972–1980 German High School Istanbul, Turkey

1980–1986 Medical School, University of Heidelberg, Germany

1984–1988 Training for a doctorate's degree in the Institute of Immunology, Transplantation Immunology, University of Heidelberg

1988–1999 Post-Doc in the Institute of Immunology, Transplantation Immunology, University of Heidelberg

**Academic Titles**

1986 Physician; Faculty of Medicine, University of Heidelberg

1988 M.D.; Faculty of Medicine, University of Heidelberg

1999 Habilitation, Venia legendi for Immunology, Associate Professor of Immunology; Faculty of Medicine, University of Heidelberg

2005 Professor of Immunology; University of Heidelberg

2021 Visiting Professor of Immunology; Koç University

**Further Qualifications**

* Specialist for Immunogenetics (DGI Certificate)
* Education Certificate of DGI for Immunogenetics
* European Specialization in Histocompatibility&Immunogenetics (ESHI Diploma)

**Current Position**

Director of Transplant Immunology Research Center of Excellence TIREX, Koç University

**Previous Positions and Functions**

Academic Director, Head of Collaborative Transplant Study, EFI-accredited HLA Antibody Laboratory and the Research Lab “CTS/Biomarker Research” in the Institute of Immunology, University Hospital Heidelberg, Germany

**Functions in Scientific Societies / Journals**

* Associate Editor of Transplantation journal (since July 2014)
* Guest Editor of Frontiers in Immunology for the Research Topics “Transplantation of Marginal Organs” and “T-cell and Antibody-mediated rejection after organ transplantation in the post-COVID-19 era – diagnosis, immunological risk evaluation and therapy”
* Reviewer for all transplantation journals
* Past-President of the German Society for Immunogenetics (2010-2012)
* Past-Secretary of the German Society for Immunogenetics (2004-2009)
* Past-Chair and current member of the “Organ Transplantation Committee” of the German Society for Immunogenetics
* Past-Chair and member of the “Immunology Committee” of the German Transplantation Society
* Previous accreditation inspector of the European Federation for Immunogenetics (EFI)
* Previous elected member of the Eurotransplant Management Board (renamed in 2020 to Council of Medicine and Science)
* Previous elected member of the Tissue Typers Advisory Committee of Eurotransplant
* Previous member of the Executive Board of German Transplantation Society

**Organization of Scientific Meetings**

* Organizer of the 2nd European CTS Expert Meeting “Innovative Approaches in Organ Transplantation” 2021 in Heidelberg, Germany
* Organizer of the 1st European CTS Expert Meeting “Transplantation of Marginal Organs” 2018 in Heidelberg, Germany
* Organizer of the 31st Congress of the European Federation for Immunogenetics (EFI) 2017 in Mannheim, Germany
* Organizer of the 1st Summer School of the German Society for Immunogenetics 2013 in Cesme-Izmir, Turkey
* Organizer and President of the 21st Annual Meeting of the German Society for Immunogenetics 2013 in Heidelberg, Germany
* Organizer of the Histocompatibility Session of the World TTS Congress in Berlin 2012
* Co-Organizer of the 20th Annual Meeting of the German Society for Immunogenetics 2012 in Cologne, Germany
* Organizer of the Educational Session at the European Society for Immunogenetics in 2012
* Co-Organizer of the 19th Annual Meeting of the German Society for Immunogenetics 2012 in Berlin, Germany
* Co-Organizer of the Histocompatibility Session of the World TTS Congress in Vancouver 2012

**Roles in Guideline Meetings**

* Organizer of the German Guideline Meetings for the Determination of Unacceptable Antigens 2014 in Frankfurt and Heidelberg, Germany
* Advisor of the German Physician Association in Guideline Meetings for Kidney Transplantation
* Co-Organizer of the TTS Guidelines Meeting on HLA and Non-HLA Antibody Testing, Rome 2012
* Member of the Transplantation Guidelines Committee of the European Association of Urology (EAU) 2009 and 2010

**Scientific Awards, Honors**

* New Key Opinion Leader (nKOL) of The Transplantation Society (TTS) 2009
  + - Human Transplantation Immunology Award of the German Transplantation Society 2005

(10.000 EUR, sponsored by Genzyme)

* + Research Award of the German Society for Immunogenetics 2002 (500 EUR)
* Research Award of European Society for Organ Transplantation 1995

(ESOT Research Award 4.000 DM, sponsored by Biotest)

* + - Best Abstract Awards at Conferences of the European Society for Immunogenetics

EFI 1999 Crete

EFI 2004 Sofia

EFI 2005 Istanbul

* + Merit Award of the American Society for Histocompatibility and Immunogenetics 2002
* Several travel awards for international transplantation conferences

**Patent Application**

* + MIC therapy for specific immunosuppression in transplantation (PCT/EP2019/062857)

**List of Publications**

**Original Publications**

1. Terness P, **Süsal C**, Opelz G. Suppression of antibody response to allogeneic blood in rats: a model for preventing sensitization to donor-specific transfusion. Transplant Proc 17:2409-2413, 1985
2. **Süsal C**, Terness P, Opelz G. Suppression of graft-versus-host reaction in rats by pretreatment of donor cells with a non-cytotoxic immunosuppressive serum. Transplant Proc 19:572-575, 1987
3. Terness P, Kisiel U, **Süsal C**, Opelz G. Prevention of sensitization by transfusion with antibody-coated blood cells: specificity of suppression and transfer with serum or spleen cells. Transplant Proc 19:1414-1419, 1987
4. **Süsal C**, Terness P, Opelz G. Induction of B-cell tolerance to alloantigens with IgG from syngeneic rats pretreated with antibody-coated allogeneic blood cells. Transplant Proc 19:4297-4299, 1987
5. Terness P, Schiffl R, **Süsal C**, Opelz G. Induction of a suppressive serum factor, prevention of sensitization, and prolongation of kidney graft survival in rats by transfusion with antibody-coated blood cells. Transplantation 46:812-819, 1988
6. Terness P, **Süsal C**, Opelz G. IgG-anti-immunoglobulin induced by immunization with antibody-coated cells: mechanism for B-cell suppression? Transplant Proc 21:153-155, 1989
7. **Süsal C**, Guo Z, Terness P, Opelz G. Role of anti-IgG autoantibodies in kidney transplantation. Immunol Lett 26:121-125, 1990
8. **Süsal C**, Guo Z, Terness P, Padanyi, A, Petranyi G, Opelz G. Induction of anti-F(ab’)2γ antibodies by buffy coat transfusions and their effect in kidney transplantation. Transplant Proc 22:1893-1984, 1990
9. Terness P**, Süsal C**, Guo Z, Opelz G. Fc-dependent suppression of “in vitro” B-cell response by IgG of alloimmunized rats. Transplant Proc 22:1957-1959, 1990
10. Terness P, **Süsal C**, Baur C, Opelz G. A B-cell-suppressive IgG-anti-immunoglobulin antibody induced by alloimmunization. Transplantation 50:502-505, 1990
11. **Süsal C**, Terness P, Opelz G. An experimental model for preventing alloimmunization against platelet transfusions by pretreatment with antibody-coated cells. Vox Sang 59:209-215, 1990
12. Terness P, Schiffl R, **Süsal C**, Guo Z, Opelz G. Long-lasting kidney graft survival after immunization with antibody-coated blood cells: mediation by immunosuppressive autoantibodies. Immunol Lett 26:139-144, 1990
13. **Süsal C**, Daniel V, Oberg HH, Terness P, Huth-Kühne A, Zimmermann R, Opelz G. Striking inverse association of IgG-anti-Fab antibodies and CD4 cell counts in patients with AIDS/ARC. Blood 79:954-957, 1992
14. **Süsal C**, Groth J, Oberg HH, Terness P, May G, Staehler G, Opelz G. Pretransplant serum IgG-anti-F(ab')2γ activity and kidney graft outcome: comparison of results obtained at two centers. Transpl Int 5:625-626, 1992
15. Terness P, **Süsal C**, Baur C, Opelz G. An immunoglobulin-specific autoantibody occurring during alloimmunization suppresses the antibody response. Transpl Int 5:559-560, 1992
16. **Süsal C**, Lewin IV, Stanworth DR, Terness P, Daniel V, Oberg HH, Huth-Kühne A, Zimmermann R, Opelz G. Anti-IgG autoantibodies in HIV-infected hemophilia patients. Vox Sang 62:224-229, 1992
17. **Süsal C**, Groth J, Oberg HH, Terness P, May G, Opelz G. The association of kidney graft outcome with pretransplant serum IgG-anti-F(ab')2γ activity. Transplantation 54:632-635, 1992
18. **Süsal C**, Groth J, Tanzi-Fetta F, Kirste G, Dörr C, Terness P, May G, Stähler G, Opelz G. Characterization of protective anti-Fab autoantibodies in kidney graft recipients. Transplant Proc 24:2523-2526, 1992
19. Terness P, Thies JC, Koru T, Daniel V, Otto G, **Süsal C**, Opelz G. Prolongation of cardiac allograft survival in rats by immunization with antibody-coated blood cells: changes in the T-cell compartment. Transplant Proc 24:2562-2564, 1992
20. Terness P, **Süsal C**, Opelz G. Restriction mechanisms of B cell regulation by a physiological IgG-anti-immunoglobulin autoantibody. Immunobiol 185:303-313, 1992
21. Terness P, Berteli A, **Süsal C**, Opelz G. Regulation of antibody response by an IgG-anti-Ig autoantibody occurring during alloimmunization. II. Selective inactivation of antigen receptor-occupied B cells. Transplantation 54:92-96, 1992 **(**
22. Daniel V, **Süsal C**, Prodeus AP, Weimer R, Zimmermann R, Huth-Kühne A, Opelz G. CD4+ lymphocyte depletion in HIV infected patients is associated with gp120-immunoglobulin-complement attachment to CD4+ cells. Vox Sang 64:31-36, 1992
23. **Süsal C**, Kröpelin M, Daniel V, Opelz G. Molecular mimicry between HIV-1 and antigen-receptor molecules: a clue to the pathogenesis of AIDS. Vox Sang 65:10-17, 1993
24. Daniel V, **Süsal C**, Weimer R, Zimmermann R, Huth-Kühne A, Opelz G. Association of T cell and macrophage dysfunction with surface gp120-immunoglobulin-complement complexes in HIV-infected patients. Clin Exp Immunol 93:152-156, 1993
25. **Süsal C**, Daniel V, Doerr C, Zimmermann R, Huth-Kühne A, Opelz G. IgA-anti-Fab autoantibodies and disease progression in AIDS. Immunol Lett 36:27-30, 1993
26. **Süsal C**, Hoffmann GW, Daniel V, Grant M, Opelz G. Complementarities and network interactions in AIDS. J Autoimmun 6:601-610, 1993
27. **Süsal C**, Oberg HH, Daniel V, Doerr C, Terness P, Huth-Kühne A, Zimmermann R, Opelz G. Isotypes and IgG-subclasses of anti-Fab antibodies in human immunodeficiency virus-infected hemophilia patients. Vox Sang 66:37-45, 1994
28. **Süsal C**, Maier H, Lorenz K, Opelz G. Association of IgA-anti-Fab autoantibodies with disease stage in patients with head and neck cancer. Proc XV World Congr ORL, Head Neck Surg 3:1106-1109, 1994
29. **Süsal C**, Maier H, Lorenz K, Opelz G. Association of disease stage in head and neck cancer with IgA-anti-Fab autoantibodies. Int J Cancer 57:47-50, 1994
30. **Süsal C**, Dörr C, Groth J, May G, Opelz G. Pretransplant serum IgA concentration and IgA-anti-Fab autoantibody activity as prognostic indicators of kidney graft survival. Transpl Int 7:586-589, 1994
31. **Süsal C**, Kirschfink M, Kröpelin M, Daniel V, Opelz G. Complement activation by recombinant HIV-1 glycoprotein gp120. J Immunol 152:6028-6034, 1994
32. Toth FD, **Süsal C**, Ujhelyi E, Banhegyi D, Kiss J, Daniel V, Nagy I, Opelz G, Füst G. Comparative study of antibodies that are associated with disease progression in HIV-disease. Immunol Lett 41:33-36, 1994
33. Prohaska Z, Hidvegi T, Ujhelyi E, Stoiber H, Dierich MP, **Süsal C**, Füst G. Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1. Immunology 85:184-189, 1994
34. **Süsal C**, Wiesel M, Staehler G, Groth J, May G, Opelz G. Excellent kidney graft survival in patients with high pretransplant serum IgA concentrations and IgA-anti-Fab autoantibody activity. Transplant Proc 27:1072-1074, 1995
35. **Süsal C**, Kröpelin M, Wiesel M, Staehler G, Groth J, May G, Opelz G. Pretransplant IgA-anti-hinge and IgA-anti-Fab autoantibody activity is associated with good kidney graft survival. Transplant Proc 27:2663-2665, 1995
36. Daniel V, **Süsal C**, Weimer R, Zipperle S, Kröpelin M, Zimmermann R, Huth-Kühne A, Opelz G. Sequential occurrence of IgM, IgM/IgG, and gp120-IgM/IgG-complement complexes on CD4+ lymphocytes in relation to CD4+ blood lymphocyte depletion in HIV+ hemophilia patients: results of a 10-year study. Immunol Lett 47:97-102, 1995
37. Daniel V, **Süsal C**, Weimer R, Zipperle S, Kröpelin M, Zimmermann R, Huth-Kühne A, Gerhard I, Maier H, Opelz G. CD8+ lymphocyte decrease in HIV disease: association with anti-CD4+ but not with anti-CD8+ lymphocyte autoantibodies. Vox Sang 70:86-91, 1996
38. Daniel V, **Süsal C**, Weimer R, Zipperle S, Kröpelin M, Zimmermann R, Huth-Kühne A, Opelz G. Association of T-cell dysfunction with the presence of IgG autoantibodies on CD4+ lymphocytes in hemophilia patients: results of a 10-year study. Clin Exp Immunol 104:4-10, 1996
39. **Süsal C**, Kirschfink M, Kröpelin M, Daniel V, Opelz G. Identification of complement activation sites in the HIV-1 glycoprotein gp120. Blood 87:2329-2336,
40. **Süsal C**, Kröpelin M, Groth J, Wiesel M, May G, Carl S, Staehler G, Opelz G. Protective effect of autoantibodies against the hinge region of human IgG in kidney graft recipients. Transplantation 62:1534-1536, 1996
41. Lorenz KJ, **Süsal C**, Opelz G, Maier H. Illness stage and IgA-anti-Fab/F(ab’)2 autoantibody activity in serum of patients with malignant head-neck tumors. Laryngorhinootologie 75:764-768, 1996
42. **Süsal C**, Wiesel M, Schönemann C, Groth J, Carl S, Staehler G, May G, Opelz G. Presensitization and HLA match influence the predictive power of pretransplant serum IgA and IgA-anti-Fab autoantibodies in kidney graft recipients. Transplant Proc 29:1444-1446, 1997
43. Kissler S, **Süsal C**, Opelz G. Anti-MIP-1alpha and anti-RANTES antibodies: new allies of HIV-1? Clinical Immunol Immunpathol 84:338-341, 1997
44. Lorenz KJ, **Süsal C**, Opelz G, Maier H. Relationship between progression of disease and immunoglobulin A-anti-Fab-/F(ab’)2 autoantibodies in patients with head and neck cancer. Otolaryngol Head Neck Surg 118:130-136, 1998
45. Pfeiffer KA, Sillem M, Daniel V, Kirschfink M, **Süsal C**, Runnebaum B, Gerhard I. Activated autologous blood therapy in recurrent spontaneous abortion: results of a pilot study. Hum Reproduction 13:491-497, 1998
46. Daniel V, **Süsal C**, Weimer R, Zipperle S, Kröpelin M, Melk A, Zimmermann R, Huth-Kühne A, Opelz G. Association of viral load in plasma samples of HIV-infected hemophilia patients with autoantibodies and gp120-containing immune complexes on CD4+ lymphocytes. Immunol Lett 60:179-187, 1998
47. Kröpelin M, **Süsal C**, Daniel V, Opelz G. Inhibition of HIV-1 rgp120 binding to CD4+ T cells by monoclonal antibodies directed against the gp120 C1 or C4 region. Immunol Lett 63:19-25, 1998
48. Prohaszka Z, Daha MR, **Süsal C**, Daniel V, Szlavik J, Banhegyi D, Nagy K, Varkonyi V, Horvath A, Ujhelyi E, Toth FD, Uray K, Hudecz F, Füst G. C1q autoantibodies in HIV infection: correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins. Clin Immunol 90:247-255, 1999
49. Doran TJ, **Süsal C**, Opelz G, Geczy AF. IgA class antibodies and flow cytometric crossmatching in renal transplantation. Transplantation 67:309-314, 1999
50. Marchalonis JJ, Garza A, Lake DF, Landsperger WJ, **Süsal C**. Recognition of defined epitopes by affinity-purified anti-immunoglobulin Fab autoantibodies isolated from HIV-infected humans. J Mol Recognition 12:169-176, 1999
51. Daniel V, Melk A, **Süsal C**, Weimer R, Zimmermann R, Huth-Kühne A, Opelz G. CD4-depletion in HIV-infected haemophilia patients is associated with rapid clearance of immune complex-coated CD4+ lymphocytes. Clin Exp Immunol 115:477-484, 1999
52. Daniel V, **Süsal C**, Melk A, Weimer R, Kröpelin M, Zimmermann R, Huth-Kühne A, Uhle C, Opelz G. Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients. Immunol Lett 69:283-289, 1999
53. Kaioumova D, Kaioumov F, **Süsal C**. Toxicity of dimethylammonium salt of 2,4-dichlorophenoxyacetic acid in rats after oral administration. Organohalogen Compounds 42:333-336, 1999
54. **Süsal C**, Döhler B, Opelz G. Graft-protective role of high pretransplantation IgA-anti-Fab autoantibodies: confirmatory evidence obtained in more than 4000 kidney transplants. Transplantation 69:1337-1340, 2000
55. Doran TJ, Geczy AF, Painter D, McCaughan G, Sheil AG, **Süsal C**, Opelz G.A large, single center investigation of the immunogenetic factors affecting liver transplantation. Transplantation 69:1491-1498, 2000
56. Kaioumova D, **Süsal C**, Opelz G. Induction of apoptosis in human lymphocytes by the herbicide 2,4-dichlorophenoxyacetic acid. Hum Immunol 62:64-74, 2001
57. Daniel V, **Süsal C**, Weimer R, Zimmermann R, Huth-Kühne A, Opelz G. Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases. AIDS Res Hum Retrovir 17:329-335, 2001
58. Daniel V, Huber W, Bauer K, **Süsal C**, Conradt C, Opelz G. Associations of blood levels of PCB, HCH, and HCB with numbers of lymphocyte subpopulations, in vitro lymphocyte response, plasma cytokine levels, and immunoglobulin autoantibodies. Environ Health Perspect 109:173-178, 2001
59. Daniel V, **Süsal C**, Weimer R, Zimmermann R, Huth-Kühne A, Opelz G. Association of immune complexes and plasma viral load with CD4+ cell depletion, CD8+DR+ and CD16+ cell counts in HIV+ hemophilia patients. Implications for the immunopathogenesis of HIV-induced CD4+ lymphocyte depletion. Immunol Lett 76:69-78, 2001
60. Daniel V, Huber W, Bauer K, **Süsal C**, Mytilineos M, Melk A, Conradt C, Opelz G. Association of elevated blood levels of pentachlorophenol (PCP) with cellular and humoral immunodeficiencies. Arch Environ Med 56:77-83, 2001
61. **Süsal C**, Opelz G. Predictive power of ELISA-detected anti-HLA class I antibodies in pediatric kidney transplantation. Transplant Proc 33:1730-1731, 2001
62. Kaioumova D, Kaioumov F, Opelz G, **Süsal C**. Toxic effects of the herbicide 2,4-dichlorophenoxyacetic acid on lymphoid organs of the rat. Chemosphere 43:801-805, 2001
63. Pelzl S, Opelz G, Wiesel M, Schnülle P, Schönemann C, Döhler B, **Süsal C**. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 73:3-6, 2002
64. **Süsal C**, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 73:1269-1273, 2002
65. **Süsal C**, Pelzl S, Döhler B, Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 13:1650-1656, 2002
66. Daniel V, Huber W, Bauer K, **Süsal C**, Conradt C, Opelz G. Associations of dichlorodiphenyltrichloroethane (DDT) 4.4 and dichlorodiphenyldichloroethylene (DDE) 4.4 blood levels with plasma IL-4. Arch Environ Health 57:541-547, 2002
67. Simon T, Opelz G, Weimer R, Wiesel M, Feustel A, Ott RC, **Süsal C**. The effect of ATG on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant period. Clin Transplant 17:217-224, 2003
68. Pelzl S, Opelz G, Daniel V, Wiesel M, **Süsal C**. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 75:421-423, 2003
69. Daniel D, Opelz G, Mulder A, **Süsal C**. Induction of apoptosis in human lymphocytes by allele-specific human anti-HLA class I antibodies. Transplantation 75:1380-1386, 2003
70. Simon T, Opelz G, Wiesel M, Ott RC, **Süsal C**. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant 3:1121-1127, 2003
71. **Süsal C**, Pelzl S, Opelz G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 76:1231-1232, 2003
72. Daniel D, **Süsal C**, Kopp B, Opelz G, Terness P. Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. Int Immunopharmacol 3:1791-1801, 2003
73. **Süsal C**, Pelzl S, Simon T, Opelz G. Advances in pre- and posttransplant immunological testing in kidney transplantation. Transplant Proc 36:29-34, 2004
74. Simon T, Opelz G, Wiesel M, Pelz S, Ott RC, **Süsal C**. Serial peripheral blood interleukin-18 and perforin gene expression measurements for prediction of acute kidney graft rejection. Transplantation 77:1589-1595, 2004
75. Sadeghi M, Daniel V, Naujokat C, **Süsal C**, Weimer R, Huth-Kühne A, Zimmermann R, Opelz G. Dissociation of CD4(+) cell counts from viral load and association with immune complexes in HIV(+) hemophilia patients. Immunol Lett 91:23-32, 2004
76. Daniel D, Opelz G, Mulder A, Kleist C, **Süsal C**. Pathway of apoptosis induced in Jurkat T lymphocytes by anti-HLA class I antibodies. Human Immunol 65:189-199, 2004
77. **Süsal C**, Opelz G. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I. Human Immunol 65:810-816, 2004
78. Weimer R, Staak A, **Süsal C**, Streller S, Yildiz S, Pelzl S, Renner F, Dietrich H, Daniel V, Rainer L, Kamali-Ernst S, Ernst W, Padberg W, Opelz G. ATG induction therapy: long-term effects on Th1 but not on Th2 responses. Transpl Int 18:226-236, 2005
79. Alvarez CM, Opelz G, Giraldo MC, Pelzl S, Renner F, Weimer R, Schmidt J, Arbeláez M, García LF, **Süsal C**. Evaluation of T cell receptor repertoires in patients with long-term renal allograft survival. Am J Transplant 5:746-756, 2005
80. Weimer R, **Süsal C**, Yildiz S, Streller S, Pelzl S, Staak A, Renner F, Dietrich H, Daniel V, Feuring E, Kamali-Ernst S, Ernst W, Padberg W, Opelz G. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. Transplant Proc 37:1776-1778, 2005
81. Weimer R, Staak A, **Süsal C**, Streller S, Yildiz S, Pelzl S, Renner F, Dietrich H, Daniel V, Rainer L, Kamali-Ernst S, Ernst W, Padberg W, Opelz G. ATG induction therapy: long-term effects on Th1 but not on Th2 responses. Transpl Int 18:226-236, 2005
82. [Matinlauri IH](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Matinlauri+IH%22%5BAuthor%5D), [Kyllonen LE](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Kyllonen+LE%22%5BAuthor%5D), [Salmela KT](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Salmela+KT%22%5BAuthor%5D), [Helin H](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Helin+H%22%5BAuthor%5D), [Pelzl S](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Pelzl+S%22%5BAuthor%5D), [**Süsal C**](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Susal+C%22%5BAuthor%5D). Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations. [Transplantation](javascript:AL_get(this,%20'jour',%20'Transplantation.');) 80:1809-1812, 2005
83. Staak A, Renner F, **Süsal C**, Dietrich H, Rainer L, Kamali-Ernst S, Ernst W, Padberg W, Opelz G, Weimer R. Immunoglobulin induction therapy in renal transplant recipients – effects on immunoglobulin and regulatory antibody levels. Transplant Proc 38:3483-3485, 2006
84. Weimer R, **Süsal C**, Yildiz S, Staak A, Pelzl S, Renner F, Dietrich H, Daniel V, Kamali-Ernst S, Ernst W, Padberg W, Opelz G. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. [Am J Transplant](javascript:AL_get(this,%20'jour',%20'Am%20J%20Transplant.');) 6:1865-1874, 2006
85. Sadeghi M, **Süsal C**, Daniel V, Naujokat C, Zimmermann R, Huth-Kühne A, Opelz G. Decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy. AIDS Res Hum Retroviruses 23:886-890, 2007
86. [Mahmoud K, Opelz G, Pelzl S, Daniel V, Sommerer C, Zeier M, Schmidt J, Schönemann C, Schnülle P, **Süsal C**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17452892&ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum). Evaluation of hepatocyte growth factor as a sensitive marker for early detection of acute renal allograft rejection. Transplantation 83:1035-1040, 2007
87. Günesacar R, Opelz G, Erken E, Pelzl S, Döhler B, Ruhenstroth A, **Süsal C**. VEGF 936 C/T gene polymorphism in renal transplant recipients: association of the T allele with good graft outcome. Hum Immunol 68:599-602, 2007
88. [Rodríguez LM](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Rodr%C3%ADguez%20LM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [París SC](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Par%C3%ADs%20SC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Arbeláez M](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Arbel%C3%A1ez%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Cotes JM](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Cotes%20JM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [**Süsal C**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22S%C3%BCsal%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Torres Y](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Torres%20Y%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [García LF](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Garc%C3%ADa%20LF%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Kidney graft recipients with pretransplantation HLA class I antibodies and high soluble CD30 are at high risk for graft loss. Hum Immunol 68:652-660, 2007
89. [Zou Y](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Zou%20Y%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Stastny P](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Stastny%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [**Süsal C**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22S%C3%BCsal%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Döhler B](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22D%C3%B6hler%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Opelz G](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Opelz%20G%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 357:1293-1300, 2007
90. Billing H, Rieger S, Ovens J, **Süsal C**, Melk A, Waldherr R, Opelz G, Tönshoff B. Successful treatment of chronic antibody-mediated rejection with IVIG and Rituximab in pediatric renal transplant recipients. Transplantation 86:1214-1221, 2008
91. Alvarez C, Opelz G, Garcia LF, **Süsal C**. Expression of regulatory T cell-related molecule-genes and clinical outcome in kidney transplant recipients. Transplantation 87:857-863, 2009
92. Beimler JHM, Morath C, Schmidt J, Ovens J, Opelz G, Rahmel A, Zeier M, **Süsal C**. Successful deceased donor kidney transplantation in crossmatch-positive patients with peritransplant plasma exchange and Rituximab. Transplantation 87:668-671, 2009
93. **Süsal C**, Döhler B, Sadeghi M, Ovens J, Opelz G. HLA antibodies and the occurrence of early adverse events in the modern era of transplantation. Transplantation 87:1367-1371, 2009
94. **Süsal C**, Döhler B, Opelz G. [Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report.](http://www.ncbi.nlm.nih.gov/pubmed/19375472) Hum Immunol 70:569-573, 2009
95. Opelz G, Döhler B, **Süsal C**. [Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant Study.](http://www.ncbi.nlm.nih.gov/pubmed/19375469) Hum Immunol 70:627-630, 2009
96. Németh D, Ovens J, Opelz G, Sommerer C, Döhler B, Becker LE, Gross ML, Waldherr R, Mieth M, Sadeghi M, Schmidt J, Langer RM, Zeier M, **Süsal C**. Does borderline kidney allograft rejection always require treatment? [Transplantation](javascript:AL_get(this,%20'jour',%20'Transplantation.');) 90:427-432, 2010
97. Morath C, Beimler J, Opelz G, Ovens J, Scherer S, Schmidt J, Schmied B, Gross ML, Schwenger V, Zeier M, **Süsal C**. An integrative approach for the transplantation of high-risk sensitized patients. Transplantation 90:645-653, 2010
98. Opelz G, **Süsal C**, Ruhenstroth A, Döhler B. Impact of HLA compatibility on lung transplant survival and evidence for an HLA restriction phenomenon: a collaborative transplant study report. Transplantation 90:912-917, 2010
99. **Süsal C**, Ovens J, Mahmoud K, Döhler B, Scherer S, Ruhenstroth A, Tran TH, Heinold A, Opelz G. [No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report.](http://www.ncbi.nlm.nih.gov/pubmed/21325993) Transplantation 91:883-887, 2011
100. Pavlova Y, Viklicky O, Slatinska J, Bürgelova M, **Süsal C**, Skibova J, Honsová E, Striz I, Kolesar L, Slavcev A. [Soluble CD30 and hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft.](http://www.ncbi.nlm.nih.gov/pubmed/21376809) Transpl Immunol 25:72-76, 2011
101. Morath C, Opelz G, Zeier M, **Süsal C**. [Kidney transplantation for high-risk sensitized patients - the "Heidelberg algorithm".](http://www.ncbi.nlm.nih.gov/pubmed/21486601) Transplant Proc 43:801-804, 2011
102. **Süsal C**, Döhler B, Salmela KT, Weimer, Sadeghi M, Opelz G. Posttransplant sCD30 as a predictor of kidney graft outcome Transplantation 91:1364-1369, 2011
103. Morath C, Becker LE, Leo A, Beimler J, Klein K, Seckinger J, Kihm LP, Schemmer P, Macher-Goeppinger S, Wahrmann M, Böhmig GA, Opelz G, **Süsal C**, Zeier M, Schwenger V.. ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation 93:827-834, 2012
104. Billing H, Rieger S, **Süsal C**, Waldherr R, Opelz G, Wühl E, Tönshoff B. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int 25:1165-1173, 2012
105. Morath C, Beimler J, Opelz G, Scherer S, Schmidt J, Macher-Goeppinger S, Sommerer C, Schwenger S, Zeier M, **Süsal C**.Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 25:506-517, 2012
106. Velásquez SY, **Süsal C**, Opelz G, García LF, Alvarez CM. Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure. Hum Immunol 73:1102-1108, 2012
107. Klein K, **Süsal C**, Schäfer SM, Becker LE, Beimler J, Schwenger V, Zeier M, Schemmer P, Macher-Goeppinger S, Scherer S, Opelz G, Morath C. [Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.](http://www.ncbi.nlm.nih.gov/pubmed/23357165) Atheroscler Suppl 14:199-202, 2013
108. **Süsal C**, Roelen DL, Fischer G, Campos EF, Gerbase-DeLima M, Hönger G, Schaub S, Lachmann N, Martorell J, Claas F. [Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients.](http://www.ncbi.nlm.nih.gov/pubmed/23718733) Tissue Antigens 82:83-92, 2013
109. Gombos P, Opelz G, Scherer S, Morath C, Zeier M, Schemmer P, Langer RM, **Süsal C**. [Superiority of AbCross enzyme-linked immunosorbent assay cross-match over the B-cell complement-dependent lymphocytotoxicity cross-match.](http://www.ncbi.nlm.nih.gov/pubmed/23726578) Transplant Proc 45:1383-1385, 2013
110. Velásquez SY, García LF, Opelz G, Alvarez CM, **Süsal C**. Release of soluble CD30 after allogeneic stimulation is mediated by memory T cells and regulated by IFN-γ and IL-2. Transplantation 96:154-161, 2013
111. Gombos P, Opelz G, Scherer S, Morath C, Zeier M, Schemmer P, **Süsal C**. Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am J Transplant 13:2075-2082, 2013
112. Billing H, Sander A, **Süsal C**, Ovens J, Feneberg R, Höcker B, Vondrak K, Grenda R, Friman S, Milford DV, Lucan M, Opelz G, Tönshoff B. Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients. Transpl Int 26:331-338, 2013
113. Höcker B, Fickenscher H, Delecluse HJ, Böhm S, Küsters U, Schnitzler P, Pohl M, John U, Kemper MJ, Fehrenbach H, Wigger M, Holder M, Schröder M, Billing H, Fichtner A, Feneberg R, Sander A, Köpf-Shakib S, **Süsal C**, Tönshoff B. Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study. Clin Infect Dis 56:84-92, 2013
114. Weimer R, Ettrich M, Renner F, Dietrich H, **Süsal C**, Deisz S, Padberg W, Opelz G. [ATG induction in renal transplant recipients: Long-term hazard of severe infection is associated with long-term functional T cell impairment but not the ATG-induced CD4 cell decline.](http://www.ncbi.nlm.nih.gov/pubmed/24530759) Hum Immunol 75:561-569, 2014
115. Opelz G, Morath C, **Süsal C**, Tran H, Zeier M, Döhler B. Three-year graft and patient survival following 1,420 ABO incompatible living-donor kidney transplants performed after ABO antibody reduction: Results from 101 centers. Transplantation 99:400-404, 2015
116. Günesacar R, Opelz G, Erken E, Döhler B, Ruhenstroth A, **Süsal C**. Complement C5a receptor gene 450 C/T polymorphism in renal transplant recipients: association of the CT genotype with graft outcome. Tissue Antigens 85:104-107, 2015
117. Gaiser MR, Textor S, Senger T, Schädlich S, Waterboer T, Kaufmann A, **Süsal C**, Pawlita M, Enk AH, Gissmann L, Lonsdorf AS.Evaluation of specific humoral and cellular immune responses against the major capsid L1 Protein of cutaneous wart-associated alpha-Papillomaviruses in solid organ transplant recipients. J Dermatol Sci 77:37-45, 2015
118. Opelz G, Morath C, **Süsal C**, Tran H, Zeier M, Döhler B. Three-year outcomes following 1,420 ABO incompatible living-donor kidney transplants performed after ABO antibody reduction: Results from 101 centers. Transplantation 99:400-404, 2015
119. **Süsal C**, Wettstein D, Döhler B, Morath C, Ruhenstroth A, Scherer S, Tran TH, Gombos P, Schemmer P, Wagner E, Fehr T, Živčić-Ćosić S, Balen S, Weimer R, Slavcev A, Bösmüller C, Norman DJ, Zeier M, Opelz G. A Collaborative Transplant Study Report. Association of kidney graft loss with de novo produced donor-specific and non-donor-specific HLA antibodies detected by single antigen testing. Transplantation 99:1976-1980, 2015
120. Becker LE, Siebert D, **Süsal C**, Opelz G, Leo A, Waldherr R, Macher-Goeppinger S, Schemmer P, Schaefer SM, Klein K, Beimler J, Zeier M, Schwenger V, Morath C. Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption. Transplantation 99:2364-2371, 2015
121. Richter R, **Süsal C**, Köhler S, Qidan S, Schödel A, Holschuh L, Brzoska M, Asbe-Vollkopf A, Büttner S, Betz C, Herrmann E, Gauer S, Seifried E, Geiger H, Seidl C, Hauser IA. **Pretransplant human leukocyte antigen antibodies detected by single antigen bead assay are a risk factor for long-term kidney graft loss even in the absence of donor specific antibodies.** Transpl Int 29:988-998, 2016
122. **Süsal C**, Döhler B, Ruhenstroth A, Morath C, Slavcev A, Fehr T, Wagner E, Krüger B, Rees M, Balen S, Živcic-Cosic S, Norman DJ, Kuypers D, Emonds MP, Pisarski P, Bösmüller C, Weimer R, Mytilineos J, Scherer S, Tran TH, Gombos P, Schemmer P, Zeier M, Opelz G. **Donor-specific antibodies require preactivated immune system to harm renal transplant.** EBioMedicine 9:366-371, 2016
123. Opelz G, Unterrainer C, **Süsal C**, Döhler B. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients. Nephrol Dial Transplant 31:1360-1367, 2016
124. Opelz G, Unterrainer C, **Süsal C**, Döhler B. Efficacy and safety of antibody induction therapy in the current era of kidney transplantation. Nephrol Dial Transplant 31:1730-1738, 2016
125. Schaefer SM, **Süsal C**, Opelz G, Döhler B, Becker LE, Klein K, Sickmüller S, Waldherr R, Macher-Goeppinger S, Schemmer P, Beimler J, Zeier M, Morath C. Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients. HLA 87:89-99, 2016
126. Velasquez SY, Opelz G, Rojas M, **Süsal C,** Alvarez CM. Association of CD30 transcripts with Th1 responses and proinflammatory cytokines in patients with end-stage renal disease. Hum Immunol 77:403-410, 2016
127. Fichtner A, **Süsal C**, Höcker B, Rieger S, Waldherr R, Westhoff JH, Sander A, Opelz G, Tönshoff B. Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients. Pediatr Nephrol 31:1157-1166, 2016
128. Daniel V, **Süsal C**, Scherer S, Tran H, Gombos P, Trojan K, Sadeghi M, Morath C, Opelz. **Endothelial precursor cell cross-match using Tie-2-enriched spleen cells.** Clin Transplant 31:e13118, 17 pages, 2017
129. Morath C, Zeier M, **Süsal C**. INVITED COMMENTARY **Increased risk of infection-associated death with incompatible kidney transplantations.** Transpl Int 30:1209-1211, 2017
130. Ihrig A, Maatouk I, Fink S, Pahernik S, **Süsal C**, Huber J, Hohenfellner M, Zeier M, Grüllich C. **Results of a patient survey for assessment services in renal transplant patients with a history of cancer.** Prog Transplant 4:365-368, 2017
131. Opelz G, Döhler B, Middleton D, **Süsal C.** HLA matching in pediatric kidney transplantation: HLA poorly matched living donor transplants versus HLA well matched deceased donor transplants. Transplantation 101:2789-2792, 2017
132. Morath C, Opelz G, Döhler B, Zeier M, **Süsal C**. **Influence of blood pressure and calcineurin inhibitors on kidney function after heart or liver transplantation.** Transplantation. 102:845-852, 2018
133. Unterrainer C, Döhler B, **Süsal C**. **Pitfalls in graft survival analysis.** HLA 91:80-87, 2018
134. **Süsal C**, Slavcev A, Pham L, Zeier M, Morath C. **The possible critical role of T-cell help in DSA-mediated graft loss.** Transpl Int 31:577-584, 2018
135. Fichtner A, **Süsal C**, Schröder C, Höcker B, Rieger S, Waldherr R, Westhoff JH, Sander A, Dragun D, Tönshoff B. **Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients.** Nephrol Dial Transplant 33:1065-1072, 2018
136. **Süsal C**, Zeier M. EDITORIAL - **Is there a need for additional DQ matching?** Clin J Am Soc Nephrol 13:683-684, 2018
137. Bouquegneau A, Loheac C, Aubert O, Bouatou Y, Viglietti D, Empana JP, Ulloa C, Hassan Murad M, Legendre C, Glotz D, Jackson AM, Zeevi A, Schaub S, Taupin JL, Reed EF, Friedewald JJ, Tyan DB, **Süsal C**, Shapiro R, Woodle ES, Hidalgo LG, O'Leary J, Montgomery RA, Kobashigawa J, Jouven X, Jabre P, Lefaucheur C, Loupy A. **Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.** PLoS Med 15:e1002572, 25 pages, 2018
138. Coemans M, **Süsal C**, Döhler B, Anglicheau D, Giral M, Bestard O, Legendre C, Emonds MP, Kuypers D, Molenberghs G, Verbeke G, Naesens M. **Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015.** Kidney Int 94:964-973, 2018
139. Soulillou J-P, **Süsal C**, Döhler B, Opelz G. **No increase in colon cancer risk following induction with Neu5Gc-bearing rabbit anti-T cell IgG (ATG) in recipients of kidney transplants.** Cancers 10:324-329, 5 pages, 2018
140. Rupp C, Rössler A, Zhou T, Rauber C, Friedrich K, Wannhoff A, Weiss KH, Sauer P, Schirmacher P, **Süsal C**, Stremmel W, Gotthardt DN. **Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis.** United European Gastroenterol J 6:255-262, 2018
141. Krüger B, Döhler B, Opelz G, Krämer BK, **Süsal C**. **Pulse pressure and outcome in kidney transplantation: Results from the Collaborative Transplant Study.** Transplantation 103:772-780, 2019
142. Unterrainer C, Opelz G, Döhler B, **Süsal C.** Pretransplant cancer in kidney recipients in relation to recurrent and de novo cancer incidence posttransplantation and implications for graft and patient survival. Transplantation 103:581-587, 2019
143. **Süsal C**, Döhler B. Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation – A Collaborative Transplant Study Report. Am J Transplant 9:2805-2813, 2019
144. Sexton DJ, O'Kelly P, Williams Y, Plant WD, Keogan M, Khalib K, Doyle B, Dorman A, **Süsal C**, Unterrainer C, Forde J, Power R, Smith G, Mohan P, Denton M, Magee C, de Freitas DG, Little D, O'Seaghdha CM, Conlon PJ. Progressive improvement in short-, medium- and long-term graft survival in kidney transplantation patients in Ireland - a retrospective study. Transpl Int 32:974-984, 2019
145. Ziemann M, Altermann W, Angert K, Arns W, Bachmann A, Bakchoul T, Banas B, von Borstel A, Budde K, Ditt V, Einecke G, Eisenberger U, Feldkamp T, Görg S, Guthoff M, Habicht A, Hallensleben M, Heinemann FM, Hessler N, Hugo C, Kaufmann M, Kauke T, Koch M, König IR, Kurschat C, Lehmann C, Marget M, Mühlfeld A, Nitschke M, Pego da Silva L, Quick C, Rahmel A, Rath T, Reinke P, Renders L, Sommer F, Spriewald B, Staeck O, Stippel D, **Süsal C**, Thiele B, Zecher D, Lachmann N. Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study. Clin J Am Soc Nephrol 14:1056-1066, 2019
146. Speer C, Kälble F, Nusshag C, Pego da Silva L, Schaier M, Becker LE, Klein K, Sommerer C, Beimler J, Leo A, Waldherr R, Mehrabi A, **Süsal C**, Zeier M, Morath C. Outcomes and complications following ABO-incompatible kidney transplantation performed after desensitization by semi-selective immunoadsorption - a retrospective study. Transpl Int 32:1286-1296, 2019
147. **Süsal C**, Aykut G, Morath C, Fichtner A, Unterrainer C, Scherer S, Tran TH, Mehrabi A, Zeier M, Tönshoff B. Relevance of donor-specific antibody monitoring after kidney transplantation: Findings from the Collaborative Transplant Study and the Heidelberg Transplant Center. HLA 94 Suppl 2:11-15, 2019
148. Speer C, Kälble F, Pego da Silva L, Nusshag C, Schaier M, Becker LE, Klein K, Beimler J, Sommerer C, Leo A, **Süsal C**, Mehrabi A, Zeier M, Morath C. Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion. Atheroscler Suppl 40:68-72, 2019
149. **Süsal C**, Kumru G, Döhler B, Morath C, Baas M, Lutz J, Unterrainer C, Arns W, Aubert O, Bara C, Beiras-Fernandez A, Böhmig GA, Bösmüller C, Diekmann F, Dutkowski P, Hauser I, Legendre C, Lozanovski VJ, Mehrabi A, Melk A, Minor T, Mueller TF, Pisarski P, Rostaing L, Schemmer P, Schneeberger S, Schwenger V, Sommerer C, Tönshoff B, Viebahn R, Viklicky O, Weimer R, Weiss KH, Zeier M, Živčić-Ćosić S, Heemann U. Should kidney allografts from old donors be allocated only to old recipients? Transpl Int 33:849-857, 2020
150. Houben P, Döhler B, Weiß KH, Mieth M, Mehrabi A, **Süsal C**. Differential Influence of Donor Age Depending on the Indication for Liver Transplantation-A Collaborative Transplant Study Report. Transplantation 104:779-787, 2020
151. Morath C, Döhler B, Kälble F, Pego da Silva L, Echterdiek F, Schwenger V, Živčić-Ćosić S, Katalinić N, Kuypers D, Benöhr P, Haubitz M, Ziemann M, Nitschke M, Emmerich F, Pisarski P, Karakizlis H, Weimer R, Ruhenstroth A, Scherer S, Tran TH, Mehrabi A, Zeier M, **Süsal C**. Pre-transplant HLA Antibodies and Delayed Graft Function in the Current Era of Kidney Transplantation. Front Immunol 11:1886, 2020
152. Lozanovski VJ, Döhler B, Weiss KH, Mehrabi A, **Süsal C**. The Differential Influence of Cold Ischemia Time on Outcome After Liver Transplantation for Different Indications-Who Is at Risk? A Collaborative Transplant Study Report. Front Immunol 11:892, 2020
153. Gold A, Tönshoff B, Döhler B, **Süsal C**. Association of graft survival with tacrolimus exposure and late intra-patient tacrolimus variability in pediatric and young adult renal transplant recipients-an international CTS registry analysis. Transpl Int 33:1681-1692, 2020
154. Echterdiek F, Schwenger V, Döhler B, Latus J, Kitterer D, Heemann U, **Süsal C.** Kidneys From Elderly Deceased Donors-Is 70 the New 60? Front Immunol 10:2701, 2019
155. Morath C, Schmitt A, Kleist C, Daniel V, Opelz G, **Süsal C**, Ibrahim E, Kälble F, Speer C, Nusshag C, Pego da Silva L, Sommerer C, Wang L, Ni M, Hückelhoven-Krauss A, Czock D, Merle U, Mehrabi A, Sander A, Hackbusch M, Eckert C, Waldherr R, Schnitzler P, Müller-Tidow C, Hoheisel JD, Mustafa SA, Alhamdani MS, Bauer AS, Reiser J, Zeier M, Schmitt M, Schaier M, Terness P. Phase I trial of donor-derived modified immune cell infusion in kidney transplantation. J Clin Invest 130:2364-2376, 2020
156. Echterdiek F, Latus J, Döhler B, Schwenger V, **Süsal C**. Impact of HLA compatibility in recipients of kidneys from expanded criteria donors: A Collaborative Transplant Study Report. Int J Immunogenet 48:201-210, 2021
157. Speer C, Schaier M, Nusshag C, Töllner M, Buylaert M, Kälble F, Reichel P, Grenz J, **Süsal C**, Zeier M, Schnitzler P, Morath C, Klein K, Benning L. Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks. Vaccines 9:1130, 2021
158. Wahrmann M, Döhler B, Arnold ML, Scherer S, Mayer KA, Haindl S, Haslacher H, Böhmig GA, **Süsal C**. Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival. Front Immunol 12:724331, 2021
159. Speer C, Morath C, Töllner M, Buylaert M, Göth D, Nusshag C, Kälble F, Schaier M, Grenz J, Kreysing M, Reichel P, Hidmark A, Ponath G, Schnitzler P, Zeier M, **Süsal C**, Klein K, Benning L. Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2. Front Med 8:721286, 2021
160. Tang C, Unterrainer C, Fink A, Cinca S, Ruhenstroth A, Scherer S, Morath C, Zeier M, Mehrabi A, **Süsal C**, Tran TH. Analysis of de novo donor-specific HLA-DPB1 antibodies in kidney transplantation. HLA 98:423-430, 2021
161. Benning L, Töllner M, Hidmark A, Schaier M, Nusshag C, Kälble F, Reichel P, Buylaert M, Grenz J, Ponath G, Klein K, Zeier M, **Süsal C**, Schnitzler P, Morath C, Speer C. Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines 9:857, 2021
162. Speer C, Benning L, Töllner M, Nusshag C, Kälble F, Reichel P, Schaier M, Bartenschlager M, Schnitzler P, Zeier M, **Süsal C**, Morath C, Bartenschlager R. Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2. Kidney Int 100:700-702, 2021
163. Ibrahim EH, Aly M, Morath C, Sayed DM, Ekpoom N, Opelz G, **Süsal C**, Daniel V. Relationship of transitional regulatory B and regulatory T cells and immunosuppressive drug doses in stable renal transplant recipients. Immun Inflamm Dis 9:1252-1271, 2021
164. Speer C, Göth D, Benning L, Buylaert M, Schaier M, Grenz J, Nusshag C, Kälble F, Kreysing M, Reichel P, Töllner M, Hidmark A, Ponath G, Schnitzler P, Zeier M, **Süsal C**, Morath C, Klein K. Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2. Clin J Am Soc Nephrol 16:1073-1082, 2021
165. Ibrahim EH, Aly MG, Opelz G, Morath C, Zeier M, Süsal C, Sayed DM, Hassan E, Ekpoom N, Daniel V.BMC Nephrol. Higher CD19+CD25+ Bregs are independently associated with better graft function in renal transplant recipients. BMC Nephrol 22:180, 2021
166. Echterdiek F, Latus J, Döhler B, Schwenger V, **Süsal C**. Influence of Cold Ischemia Time on the Outcome of Kidney Transplants from Donors Aged 70 Years and Above-A Collaborative Transplant Study Report. Transplantation 105:2461-2469, 2021
167. Emmerich F, Zschiedrich S, Reichenbach-Braun C, **Süsal C**, Minguet S, Pauly MC, Seidl M. Low Pre-Transplant Caveolin-1 Serum Concentrations Are Associated with Acute Cellular Tubulointerstitial Rejection in Kidney Transplantation. Molecules 26:2648, 2021
168. Fichtner A, **Süsal C**, Höcker B, Rieger S, Waldherr R, Westhoff JH, Sander A, Dragun D, Tönshoff B. Association of non-HLA antibodies against endothelial targets and donor-specific HLA antibodies with antibody-mediated rejection and graft function in pediatric kidney transplant recipients. Pediatr Nephrol 36:2473-2484, 2021
169. Gold A, Fichtner A, Choukair D, Schmitt CP, **Süsal C**, Dragun D, Tönshoff B. Kidney re-transplantation in a child across the barrier of persisting angiotensin II type I receptor antibodies. Pediatr Nephrol 36:725-729, 2021
170. Benning L, Morath C, Bartenschlager M, Nusshag C, Kälble F, Buylaert M, Schaier M, Beimler J, Klein K, Grenz J, Reichel P, Hidmark A, Ponath G, Töllner M, Reineke M, Rieger S, Tönshoff B, Schnitzler P, Zeier M, **Süsal C**, Bartenschlager R, Speer C. Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination. Clin J Am Soc Nephrol 17:98-106, 2022
171. Engels G, Döhler B, Tönshoff B, Oh J, Kruchen A, Müller I, **Süsal C**. Maternal versus paternal living kidney transplant donation is associated with lower rejection in young pediatric recipients: A Collaborative Transplant Study report. Pediatr Transplant 26: e14154, 2022
172. Lozanovski VJ, Unterrainer C, Döhler B, **Süsal C**, Mehrabi A. Outcome of Extended Right Lobe Liver Transplants. Liver Transpl 2021 (online ahead of print)
173. Benning L, Morath C, Bartenschlager M, Reineke M, Töllner M, Nusshag C, Kälble F, Reichel P, Schaier M, Schnitzler P, Zeier M, Süsal C, Bartenschlager R, Speer C. Natural SARS-CoV-2 infection results in higher neutralization response against variants of concern compared to two-dose BNT162b2 vaccination in kidney transplant recipients. Kidney Int 2021 (online ahead of print)
174. Kälble F, **Süsal C**, Pego da Silva L, Speer C, Benning L, Nusshag C, Pham L, Tran HT, Schaier M, Sommerer C, Beimler J, Mehrabi A, Zeier M, Morath C. Living donor kidney transplantation in patients with donor-specific HLA antibodies after desensitization with immunoadsorption. Front Med 8:781491, 2021
175. Houben P, Schimmack S, Unterrainer C, Döhler B, Mehrabi A, **Süsal C**. Rare Malignant Indications for Liver Transplantation: A Collaborative Transplant Study Report. Front Surg 8:678392, 2021
176. Echterdiek F, Döhler B, Latus J, Schwenger V, **Süsal C**. Influence of calcineurin inhibitor choice on outcome in kidney transplant recipients aged ≥60 years – A Collaborative Transplant Study report. Transplantation (in press)
177. Vinson AJ, Zhang X, Dahhou M, **Süsal C**, Döhler B, Sapir-Pichhadze R, Cardinal H, Melk A, Wong G, Francis A, Pilmore H, Foster BJ. Age-Dependent Sex Differences in Graft Loss After Kidney Transplantation. Transplantation 2021 (online ahead of print)
178. Vietzen H, Döhler B, Tran TH, **Süsal C**, Halloran PH, Eskandary F, Herz C, Mayer KA, Kozakowski N, Wahrmann M, Ely S, Haindl S, Puchhammer-Stöckl E, Böhmig GA. Deletion of the natural killer cell receptor NKG2C encoding KLR2C gene and kidney transplant outcome. Front Immunol (in revision)
179. Morath C, Hayek SS, Döhler B, Nusshag C, Sommerer C, Zeier M, Reiser J, **Süsal C**. Soluble urokinase receptor and mortality in kidney transplant recipients. Transplantation (in press)
180. Carapito R, Aouadi I, Verniquet M, Untrau M, Pichot A, Beaudrey T, Bassand X, Meyer S, Faucher L, Posson J, Morlon A, Kotova I, Delbos F, Walencik A, Aarnink A, Kennel A, Suberbielle C, Taupin JL, Matern BM, Spierings E, Congy-Jolivet N, Essaydi A, Perrin P, Blancher A, Charron D, Cereb N, Maumy-Bertrand M, Bertrand F, Garrigue V, Pernin V, Weekers L, Naesens M, Kamar N, Legendre C, Glotz D, Caillard S, Ladrière M, Giral, Anglicheau D, **Süsal C**, Bahram S. The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation. Nat Med (in press)

**Guideline Articles**

1. Tait BD, **Süsal C**, Gebel HM, Nickerson PW, Zachary AA, Claas FH, Reed EF, Bray RA, Campbell P, Chapman JR, Coates PT, Colvin RB, Cozzi E, Doxiadis II, Fuggle SV, Gill J, Glotz D, Lachmann N, Mohanakumar T, Suciu-Foca N, Sumitran-Holgersson S, Tanabe K, Taylor CJ, Tyan DB, Webster A, Zeevi A, Opelz G.Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 95:19-47, 2013.
2. **Süsal C**, Seidl C, Schönemann C, Heinemann FM, Kauke T, Gombos P, Kelsch R, Arns W, Bauerfeind U, Hallensleben M, Hauser IA, Einecke G, Blasczyk R. Determination of unacceptable HLA antigen mismatches in kidney transplant recipients: recommendations of the German Society for Immunogenetics. Tissue Antigens 86:317-323, 2015

**Review Articles**

1. **Süsal C**, Terness P, Opelz G. Antikörper schützen vor Antikörpern. Immunol Spektrum 6:8-10, 1989
2. Guo Z, Terness P, **Süsal C**, Opelz G. Antibody suppresses antibody response. Ellipse 23:328-332, 1990
3. Guo Z, Terness P, **Süsal C**, Opelz G. Selbstregulation der B-Lymphozyten. Immunol Spektrum 6:4-8, 1990
4. **Süsal C**, Kröpelin M, Wiesel M, Carl S, Staehler G, Groth J, May G, Opelz G. IgA-Serumspiegel als Indikator für die Dosierung von Immunsuppressiva. Perspektive Transplantation 4:13-14, 1996
5. **Süsal C**. Vorsensibilisierung – ein bald gelöstes Problem? Diatra 3:35-38, 2006
6. [Beimler JH, **Süsal C**, Zeier M](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17100695&ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum). Desensitization strategies enabling successful renal transplantation in highly sensitized patients. Clin Transplant 20 Suppl 17:7-12, 2006 **(IF 1.844)**
7. **Süsal C**, Opelz G. Options for immunologic support of renal transplantation through the HLA and immunology laboratories. Am J Transplant 7:1450-1456, 2007 **(IF 7.163)**
8. Wieland E, Olbricht CJ, **Süsal C**, Gurragchaa P, Böhler T, Israeli M, Sommerer C, Budde C, Hartmann B, Shipkova M, Oellerich M. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit 32:560-572, 2010
9. **Süsal C**, Morath C. [Current approaches to the management of highly sensitized kidney transplant patients.](http://www.ncbi.nlm.nih.gov/pubmed/21299521) Tissue Antigens 77:177-186, 2011
10. Morath C, Schmidt J, Opelz G, Zeier M, **Süsal C**. [Kidney transplantation in highly sensitized patients: are there options to overcome a positive crossmatch?](http://www.ncbi.nlm.nih.gov/pubmed/21416127) Langenbecks Arch Surg 396:467-474, 2011
11. Morath C, Opelz G, Zeier M, **Süsal C**. Recent developments in desensitization of crossmatch-positive kidney transplant recipients. Transplant Proc 44:1648-1651, 2012
12. **Süsal C**, Opelz G. [Posttransplant sCD30 as a biomarker to predict kidney graft outcome.](http://www.ncbi.nlm.nih.gov/pubmed/22037199) Clin Chim Acta 413:1350-1353, 2012
13. Morath C, Opelz G, Zeier M, **Süsal C**. [Recent developments in desensitization of crossmatch-positive kidney transplant recipients.](http://www.ncbi.nlm.nih.gov/pubmed/22841236) Transplant Proc 44:1648-51, 2012
14. **Süsal** **C**, Opelz G. [Impact of HLA matching and HLA antibodies in organ transplantation: a collaborative transplant study view.](http://www.ncbi.nlm.nih.gov/pubmed/22665239) Methods Mol Biol 882:267-77, 2012
15. Morath C, Opelz G, Zeier M, **Süsal C.** [Prevention of antibody-mediated kidney transplant rejection.](http://www.ncbi.nlm.nih.gov/pubmed/22587522) Transpl Int 25:633-645, 2012
16. Opelz G, Döhler B, Ruhenstroth A, Cinca S, Unterrainer C, Stricker L, Scherer S, Gombos P, **Süsal C**, Daniel V, Tran H. [The collaborative transplant study registry.](http://www.ncbi.nlm.nih.gov/pubmed/23465693) Transplant Rev 27: 43-5, 2013
17. Schaefer SM, **Süsal C**, Sommerer C, Zeier M, Morath C. [Current pharmacotherapeutical options for the prevention of kidney transplant rejection.](http://www.ncbi.nlm.nih.gov/pubmed/23560807) Expert Opin Pharmacother 14:1029-1041, 2013
18. **Süsal C**, Opelz G, Morath C. [Role and value of Luminex(®)-detected HLA antibodies before and after kidney transplantation.](http://www.ncbi.nlm.nih.gov/pubmed/23922544) Transfus Med Hemother 40:190-195, 2013
19. Arns W, Dragun D, Nashsna B, Sommerer C, **Süsal C**, Zeier M. Donorspezifische Antikörper bei Nierentransplantation. DSA Advisory Board. Blickpunkt Medizin. Deutsche Medizinische Wochenschrift Mai 14, 2013
20. Becker LE, **Süsal C**, Morath C. [Kidney transplantation across HLA and ABO antibody barriers.](http://www.ncbi.nlm.nih.gov/pubmed/23838650) Curr Opin Organ Transplant 18:445-54, 2013
21. **Süsal C**, Opelz G. [Current role of human leukocyte antigen matching in kidney transplantation.](http://www.ncbi.nlm.nih.gov/pubmed/23838649) Curr Opin Organ Transplant 18:438-444, 2013
22. Wettstein D, Opelz G, **Süsal C**. [HLA antibody screening in kidney transplantation: current guidelines.](http://www.ncbi.nlm.nih.gov/pubmed/24271161) Langenbecks Arch Surg 399:415-420, 2014
23. Morath C, Opelz G, Zeier M, **Süsal C**. Clinical relevance of HLA antibody monitoring after kidney transplantation. J Immunol Res 2014:845040, 2014
24. Köster L, Krupka K, Höcker B, Rahmel A, Samuel U, Zanen W, Opelz G, **Süsal C**, Döhler B, Plotnicki L, Kohl CD, Knaup P, Tönshoff B. Integrating data from multiple sources for data completeness in a web-based registry for pediatric renal transplantation - the CERTAIN Registry. Stud Health Technol Inform 216:1049, 2015
25. Kälble F, Schaier M, Schäfer S, **Süsal C**, Zeier M, Sommerer C, Morath C. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade. Expert Opin Pharmacother 18:799-807, 2017
26. Morath C, Zeier M, Döhler B, Opelz G, **Süsal C.** ABO-Incompatible kidney transplantation.Front Immunol 8:234, 2017
27. **Süsal C**, Fichtner A, Tönshoff B, Mehrabi A, Zeier M, Morath C. Clinical relevance of HLA antibodies in kidney transplantation: recent data from the Heidelberg transplant center and the collaborative transplant study.J Immunol Res 2017
28. Janszky N, **Süsal C. Circulating and urinary microRNAs as possible biomarkers in kidney transplantation.** Transplant Rev (Orlando).32:110-118, 2018
29. Hackl C, Schmidt KM, **Süsal C**, Döhler B, Zidek M, Schlitt HJ. **Split liver transplantation: Current developments.** World J Gastroenterol 24:5312-5321, 2018
30. Noble J, Jouve T, Malvezzi P, **Süsal C**, Rostaing L. Transplantation of Marginal Organs: Immunological Aspects and Therapeutic Perspectives in Kidney Transplantation. Front Immunol 10:3142, 2020
31. Kumru Sahin G, Unterrainer C, **Süsal C**. Critical evaluation of a possible role of HLA epitope matching in kidney transplantation. Transplant Rev (Orlando) 34:100533, 2020
32. Unterrainer C, Döhler B, Niemann M, Lachmann N, **Süsal C.** Can PIRCHE-II epitope matching outmatch traditional HLA matching? Front Immunol 12:631246, 2021

**Viewpoint Articles**

1. **Süsal C**, Daniel V, Opelz G. Does AIDS emerge from a disequilibrium between two complementary groups of molecules that mimic MHC? Immunol Today 17:114-119, 1996
2. Morath C, Zeier M, **Süsal C**. [Desensitization of HLA-incompatible kidney recipients.](http://www.ncbi.nlm.nih.gov/pubmed/22029993) N Engl J Med 365:1644, 2011
3. Morath C, **Süsal C**. [Transplantation: Rituximab induction only for sensitized kidney recipients?](http://www.ncbi.nlm.nih.gov/pubmed/24145326) Nat Rev Nephrol 9:703-705, 2013
4. Morath C, Zschiedrich S, Speer C, Zeier M, Döhler B, Opelz G, **Süsal** **C**. Clinical outcomes after ABO-incompatible renal transplantation. Lancet 394:1989, 2019 (Letter)

**Editorials**

1. Opelz G, **Süsal C**. A positive crossmatch and treatment with IvIg. [Am J Transplant](javascript:AL_get(this,%20'jour',%20'Am%20J%20Transplant.');) 5:2601-2602, 2005
2. **Süsal C.** [Increasing relevance of histocompatibility testing in organ transplantation.](http://www.ncbi.nlm.nih.gov/pubmed/23774634) Curr Opin Organ Transplant 18:436-467, 2013
3. **Süsal C,** Morath C. Virtual PRA replaces traditional PRA: small change but significantly more justice for sensitized patients. Transpl Int 28:708-709, 2015
4. Morath C, Zeier M, **Süsal C**, Döhler B, Opelz G. Response to A reassessment of the survival advantage of simultaneous kidney-pancreas versus kidney-alone transplantation. Transplantation 99:e175, 2015
5. **Süsal C**, Opelz G. Transplantation: desensitization and survival in kidney transplant recipients. Nat Rev Nephrol 13:196-198, 2017
6. **Süsal C,** Morath C. Is Belatacept switch safe in renal transplant recipients with donor-specific antibodies? Transplantation 103:1984-1985, 2019
7. **Süsal C**, Mueller TF, Legendre C, Schemmer P. Editorial: Transplantation of Marginal Organs-Immunological Aspects and Therapeutic Perspectives. Front Immunol 11:612576, 2020
8. Morath C, **Süsal C**. Three is not enough. Transpl Int 33:612-614, 2020

**Book Chapters**

1. Terness P, **Süsal C**, Opelz G. Immunization with antigen-bound antibody: an experimental approach to prevention of sensitization to allogeneic blood cells In: White cells and platelets in blood transfusion. Smith Sbinga CTh, Das PC, Engelfriet CP (eds). Boston, Dordrecht, Lancaster: Martinus Nijhoff Publishing pp. 68-84, 1987
2. **Süsal C**, Pelzl S, Opelz G. Relationship between kidney graft rejection and pretransplant anti-HLA antibody status and serum CD30 content. HLA 2004: Immunobiology of the Human MHC. Proceedings of the 13th International Histocompatibility Workshop and Congress. (Hansen JA and Dupont B, eds), Volume I & II, IHWG Press, Seattle, WA, USA, 2004
3. Terasaki P, Ozawa M, Castro R, Lee S, Cook D, Abdelnoor A, Bow L, Chan L, Christiansen F, Crowe D, duToit E, Esquenazi V, Fuggle S, Glehn C, Higgins N, Humar I, Jobim L, Kankonkar, Lee P, LeFor W, Mahoney R, McAlack R, Mehra N, Milford E, Naumova E, Neumann J, Orosz C, Perichon, Piazza A, Polymenidis A, Reed E, Reinsmoen N, Sada M, Saidman S, Schonenmann C, Semana G, Slavcev A, Stavropoulos-Giokas C, **Süsal C**, Tait B, Zeevi A. 13th IHWS Chronic Rejection of Solid Organ Grafts Joint Report. M1. Prospective chronic rejection study report February 14, 2003. HLA 2004: Immunobiology of the Human MHC. Proceedings of the 13th International Histocompatibility Workshop and Congress (Hansen JA and Dupont B, eds), Volume I & II, IHWG Press, Seattle, WA, USA, 2004
4. **Süsal C**, Opelz G. Impact of HLA Matching and HLA Antibodies in Organ Transplantation. A Collaborative Transplant Study View. Immunogenetics-Methods&Applications in Clinical Practice (Christiansen F, Tait B, eds). Humana Press, New York, NY, USA, 2011
5. Duman T, Tutkak H, **Süsal C**. Antikor Taramalarında Yeni Yaklaşım Kılavuzları 2013. Transplantasyon İmmünolojisi Special Issue (Tutkak H, ed). Türkiye Klinikleri